<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338662</url>
  </required_header>
  <id_info>
    <org_study_id>H-1009-057-332</org_study_id>
    <nct_id>NCT01338662</nct_id>
  </id_info>
  <brief_title>Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist</brief_title>
  <official_title>A 10-year Observational Study of the Incidence of Dyskinesia in Patients With Early Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the onset time and severity of dyskinesia in
      amantadine or Dopamine agonist initial treated groups in Parkinson`s disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Dopamine agonist can delay the risk of dyskinesia by initiating treatment rather than
           levodopa. Amantadine is typical antidyskinetic drug. There is no data about comparison
           of risk of dyskinesia in amantadine and dopamine agonist by initiating treatment.

        2. Prospective , randomized, open label study compare the onset time and severity of
           dyskinesia between groups randomized assigned order of amantadine and dopamine agonist
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>dyskinesia onset</measure>
    <time_frame>up to 10 years from the start of durg (Amantadine or dopaimine agonsit)</time_frame>
    <description>observe duration of onset of dyskinesia from initial treatment observe until 10 years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>UPDRS, severity of dyskinesia between groups</measure>
    <time_frame>observe duration of onset of dyskinesia from initial treatment</time_frame>
    <description>observe duration of onset of dyskinesia from initial treatment observe until 10 years compare the UPDRS and severity of dyskinesia between groups</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Parkinson`s Disease</condition>
  <arm_group>
    <arm_group_label>Group A-1</arm_group_label>
    <description>study enroll number 3n+1 (N=0,1,2...)
initial treatment- amantadine
add levodopa when the patient become to need further treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A-2</arm_group_label>
    <description>study enroll number 3n+2 (N=0,1,2...)
initial treatment: amantadine
add dopamine agonist when the patient become to need further treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>study enroll number 3n+3 (N=0,1,2...)
initial treatment: dopamine agonist
add levodopa when the patient become to need further treatment. but cannot use amantadine</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        outpatient clinic in SNUH
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  30&lt;age&lt;60

          -  IPD

          -  H &amp; Y&lt;3

        Exclusion Criteria:

          -  previous dopaminergic medication history

          -  dyskinesia

          -  Parkinson plus

          -  clinically significant or unstable medical or surgical condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beom S Jeon, MD, PhD</last_name>
    <phone>82-2-2072-2876</phone>
    <email>brain@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Eun Kim, MD</last_name>
    <phone>82-2-2072-1219</phone>
    <email>yeksl99@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beom S Jeon</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beom S Jeon, MD, PhD</last_name>
      <phone>82-2-2072-2876</phone>
      <email>brain@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Eun Kim, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med. 2000 May 18;342(20):1484-91.</citation>
    <PMID>10816186</PMID>
  </reference>
  <reference>
    <citation>Montastruc JL, Rascol O, Senard JM, Rascol A. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry. 1994 Sep;57(9):1034-8.</citation>
    <PMID>8089666</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2011</study_first_submitted>
  <study_first_submitted_qc>April 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2011</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>BS Jeon</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson`s disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
    <mesh_term>Dyskinesias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Amantadine</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

